Teva’s celiac drug meets main goal in mid-stage trial
Teva said its experimental immune-disorder drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the main goal of its mid-stage trial. U.S.-listed shares were up over 4% in premarket.